Comparing early biologic treatment to standard care for newly diagnosed Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study compares two treatment approaches for newly diagnosed moderate-to-severe Crohn's disease: a powerful biologic called mirikizumab given early (top-down) versus the standard approach with azathioprine. The goal is to see if starting with the stronger treatment leads to better control of inflammation and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with Crohn's disease within the past year.
- Your Crohn's disease should be moderate to severe, with active symptoms.
- You must not have taken advanced treatments (like biologics) or immunosuppressants (like azathioprine) before.
- You must not have had any Crohn's-related surgery in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This trial tests if taking a new drug (LY4395089) with mirikizumab works better than mirikizumab alone for adults with Crohn's disease. It also looks at the safety of these treatments.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Hear when a new Chrohn's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.